CN104739843A - Medicine composition for treating dental ulcer - Google Patents
Medicine composition for treating dental ulcer Download PDFInfo
- Publication number
- CN104739843A CN104739843A CN201510176661.4A CN201510176661A CN104739843A CN 104739843 A CN104739843 A CN 104739843A CN 201510176661 A CN201510176661 A CN 201510176661A CN 104739843 A CN104739843 A CN 104739843A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- pharmaceutical composition
- oral ulcer
- phenylbutazone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 229940079593 drug Drugs 0.000 title claims description 4
- 208000025865 Ulcer Diseases 0.000 title abstract description 6
- 231100000397 ulcer Toxicity 0.000 title abstract description 5
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 229960002895 phenylbutazone Drugs 0.000 claims abstract description 11
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 208000002193 Pain Diseases 0.000 claims abstract description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 22
- 235000019156 vitamin B Nutrition 0.000 claims description 22
- 239000011720 vitamin B Substances 0.000 claims description 22
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 21
- 208000007117 Oral Ulcer Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims description 11
- 229960002800 prednisolone acetate Drugs 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000006192 thin film tablet Substances 0.000 claims description 2
- 210000003026 hypopharynx Anatomy 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- 206010018291 Gingival swelling Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010068319 Oropharyngeal pain Diseases 0.000 abstract 1
- 201000007100 Pharyngitis Diseases 0.000 abstract 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229930003471 Vitamin B2 Natural products 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 235000019164 vitamin B2 Nutrition 0.000 abstract 1
- 239000011716 vitamin B2 Substances 0.000 abstract 1
- 208000001387 Causalgia Diseases 0.000 description 10
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 10
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000276489 Merlangius merlangus Species 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YADZBEISHVCBSJ-UHFFFAOYSA-N [I].OCC(O)CO Chemical compound [I].OCC(O)CO YADZBEISHVCBSJ-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940102708 phenylbutazone 100 mg Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicine composition for treating dental ulcer. The medicine composition comprises phenylbutazone, prednisone acetate, vitamin B1 and vitamin B2, and the medicinal materials are synergized to achieve the effects of relieving pain, diminishing inflammation, relieving allergy, supplying vitamins caused by dental ulcer and accelerating treatment of dental ulcer diseases. The medicine composition is also used for treating gum swelling and sore throat.
Description
Technical field:
The present invention relates to a kind of pharmaceutical composition being used for the treatment of oral ulcer, belong to field of medicaments.
Background technology:
Oral ulcer, also known as " aphtha ", is the superficial ulcer occurring in oral mucosa, size can from the grain of rice to Semen Glycines size, circular or oval, ulcer surface is recessed, congested around, can because of irritable food or initiation causalgia of speaking.Although what serious disease is oral ulcer be not, be characterized in hurt like hell, uncomfortable, bring very large impact to work and life.Therefore can not be ignored.At present, the cause of disease and mechanism of causing a disease are still indefinite, and inducement may be local wound, psychentonia, food, medicine, hormonal readiness change and the shortage of vitamin or trace element.One or two week general can spontaneous recovery.Within 1 year, can fall ill for several times, also can fall ill several times for one month, even new and old pathological changes alternately occurs.Doctor trained in Western medicine to take antibiotic medicine treatment, or takes vitaminization, or local iodine glycerol is treated.Also take Chinese herbal medicine to treat.But said medicine or therapeutic effect poor, or it is slow to take effect.Treatments period fails effectively to alleviate the causalgia that oral ulcer is brought.Be difficult to improve pain to patient in the impact worked, live and sleep.
Summary of the invention:
In order to overcome the deficiencies in the prior art, the present invention according to the cause of disease and state of an illness feature, provide a kind of and prepare conveniently, medicine source is wide, at the bottom of cost, the pharmaceutical composition of evident in efficacy, reliable effect, short treating period.
The technical solution adopted for the present invention to solve the technical problems is: a kind of pharmaceutical composition being used for the treatment of oral ulcer, is characterized in that: be made up of the medicine of following weight portion: Phenylbutazone 10-600 part, prednisolone acetate 1-60 part, vitamin B
15-50 part, vitamin B
23-50 part.
The preferred technical solution of the present invention is: a kind of pharmaceutical composition being used for the treatment of oral ulcer, is characterized in that: be made up of the medicine of following weight portion: Phenylbutazone 100-200 part, prednisolone acetate 5-10 part, vitamin B
110-20 part, vitamin B
25-10 part.
The preferred technical solution of the present invention is: a kind of pharmaceutical composition being used for the treatment of oral ulcer, is characterized in that: be made up of the medicine of following weight portion: Phenylbutazone 100 parts, prednisolone acetate 5 parts, vitamin B
110 parts, vitamin B
25 parts.
The preferred technical solution of the present invention is: a kind of pharmaceutical composition being used for the treatment of oral ulcer, is characterized in that: be made up of the medicine of following weight portion: Phenylbutazone 50 parts, prednisolone acetate 3 parts, vitamin B
110 parts, vitamin B
25 parts.
The feature science collocation of the reason that pharmaceutical composition of the present invention is fallen ill according to oral ulcer and morbidity, Synergistic treatment.Phenylbutazone has analgesic efficacy.Prednisolone acetate is used for antiinflammatory, antiallergic.Vitamin B
1and vitamin B
2supplement the vitamin causing one of oral ulcer reason to lack.Owing to arranging in pairs or groups rationally, rapid-action, short treating period, times for spraying is few.Avoid the side effect that Long-term Hormone brings.
Pharmaceutical composition of the present invention also can with pharmaceutically acceptable carrier combinations, pharmaceutical methods conveniently makes conventional preparation: such as powder, tablet, sugar coated tablet, thin film tablet, granule, capsule, containing tablet, injection, oral liquid.
Detailed description of the invention:
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.
Embodiment 1: get Phenylbutazone 10g, prednisolone acetate 500mg, vitamin B
11g, vitamin B
2500mg, incapsulates shell after pulverizing respectively and can be made into capsule 100.Every contains: Phenylbutazone 100mg, prednisolone acetate 5mg, vitamin B
110mg, vitamin B
25mg.
Consumption and usage: every day 2-3 time, each 1-2 grain.Causalgia can reduce to each 1 after alleviating.Must not take more than 6 in 24 hours.
Pharmaceutical composition of the present invention must not take medicine continuously more than 5 days.The bad person's forbidding of anemia of pregnant woman, baby, aspirin-sensitive person, edema, hypertension, psychosis, epilepsy, bronchial asthma, heart disease and Liver and kidney function.
For showing the therapeutic effect of medicine of the present invention to oral ulcer, the present inventor has carried out system clinical observation to 38 routine oral ulcer, and its curative effect statistical result is as follows:
19 years old-68 years old age.Man 22 people, female 16 people.Effective alleviation causalgia 38 people (100%), fully recovered in 3 days 28 people (73.6%), and fully recovered in 5 days 9 people (23.6%), within 5 days, fails recovery from illness 1 people (2.6%).Total effective rate is 97.3%.
Treatment example 1. patient Chen, female, within 56 years old, Symptoms is: in oral cavity, many places occur congested, have no and fester, more than 2 days persistent period.Causalgia is obvious, speaks and feed is hindered, impact sleep.Take medicine to the second day of the present invention, causalgia is alleviated substantially, and congested unclear location shows.3rd day, symptom all disappeared, and cured.
Treatment example 2. patient Lee, man, 42 years old, Symptoms was: in lip, there is an about diameter 4mm aphtha at gingiva place in lower-left, and surrounding is congested, middle whiting, and more than 3 days persistent period, causalgia is obvious, and feed is hindered.Take medicine of the present invention 2 after 3 hours causalgia slow down to some extent.Medication in second day 2 times, causalgia is significantly alleviated, and congested and whiting position is desalinated to some extent.Within 3rd day, reduce to medication 1, take 3 times, causalgia disappears substantially, congested not obvious with whiting position.4th day, symptom all disappeared, recovery from illness.
Claims (6)
1. be used for the treatment of a pharmaceutical composition for oral ulcer, it is characterized in that: crude drug is by weight prepared from: Phenylbutazone 10-600 part, prednisolone acetate 1-60 part, vitamin B
15-50 part, vitamin B
23-50 part forms.
2. treat the pharmaceutical composition of oral ulcer according to claim 1, can be by weight: Phenylbutazone 50-200 part, prednisolone acetate 3-10 part, vitamin B
110-20 part, vitamin B
25-10 part.
3. according to claim 1-2, treat the pharmaceutical composition of oral ulcer, can be by weight: Phenylbutazone 100 parts, prednisolone acetate 5 parts, vitamin B
110 parts, vitamin B
25 parts.
4. according to claim 1-2, treat the pharmaceutical composition of oral ulcer, can be by weight: Phenylbutazone 50 parts, prednisolone acetate 3 parts, vitamin B
110 parts, vitamin B
25 parts.
5. according to claim 1-4, treat the pharmaceutical composition of oral ulcer, can make powder, tablet, sugar coated tablet, thin film tablet, granule, capsule, containing tablet, injection, oral liquid.
6. according to claim 1-5, treat the pharmaceutical composition of oral ulcer, may be used for treatment tooth meat distending pain, laryngopharynx swelling and pain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510176661.4A CN104739843A (en) | 2015-04-15 | 2015-04-15 | Medicine composition for treating dental ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510176661.4A CN104739843A (en) | 2015-04-15 | 2015-04-15 | Medicine composition for treating dental ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104739843A true CN104739843A (en) | 2015-07-01 |
Family
ID=53580467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510176661.4A Pending CN104739843A (en) | 2015-04-15 | 2015-04-15 | Medicine composition for treating dental ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104739843A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105056065A (en) * | 2015-08-12 | 2015-11-18 | 彭刘平 | Traditional Chinese medicine composition for treating sphagitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1543358A (en) * | 2000-12-19 | 2004-11-03 | �ÿ���˹ϵͳ��ѧ���»� | Method and composition for protecting gastrointestinal tract and improving clinical efficacy by using preparations containing lecithin oil and non-steroidal anti-inflammatory drugs |
-
2015
- 2015-04-15 CN CN201510176661.4A patent/CN104739843A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1543358A (en) * | 2000-12-19 | 2004-11-03 | �ÿ���˹ϵͳ��ѧ���»� | Method and composition for protecting gastrointestinal tract and improving clinical efficacy by using preparations containing lecithin oil and non-steroidal anti-inflammatory drugs |
Non-Patent Citations (1)
| Title |
|---|
| 张丽梅: "口腔粘膜疾病的药物治疗", 《医药导报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105056065A (en) * | 2015-08-12 | 2015-11-18 | 彭刘平 | Traditional Chinese medicine composition for treating sphagitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505050A5 (en) | ||
| CN101474192A (en) | Veramyst medicinal preparation and preparation method | |
| CN103083500A (en) | Chinese medicinal composition treating toxoplasmosis | |
| CN104739843A (en) | Medicine composition for treating dental ulcer | |
| CN102178843B (en) | Chinese medicinal powder for treating dental ulcer and stomatitis | |
| CN101152196A (en) | Application of Panax notoginseng saponins and its monomers in the preparation of drugs for treating depression | |
| CN102416066A (en) | A traditional Chinese medicine preparation for treating throat and oral diseases and its preparation method | |
| CN102380087A (en) | Chinese medicinal composition for treating cough and dyspnea | |
| CN102441034A (en) | Medicine for treating allergic rhinitis | |
| CN103463236B (en) | Medicinal composition and preparation method thereof | |
| CN103211968B (en) | Medicine for treating swelling and aching of gum | |
| CN103479625B (en) | Application of Fluevirosines A in preparation of blood sugar reducing medicines | |
| CN103690752B (en) | A kind of medicament for the treatment of orthodontic gingivitis | |
| CN110420209B (en) | Pharmaceutical composition for treating diabetic peripheral neuralgia and application thereof | |
| CN102293833A (en) | Drug for treating pulmonary fibrosis in patient received allogeneic kidney transplantation surgery | |
| CN102343037A (en) | Drug with effects of bacterium resistance, disinfection, blood circulation promotion, blood stasis removal, immunity improvement, life prolonging and aging delay | |
| CN105012439A (en) | Medicine for treating gastritis | |
| CN101579387B (en) | Medicinal composition for treating anorexia nervosa and preparation method thereof | |
| CN105030982A (en) | Traditional Chinese medicine lotion for treating haemorrhoids and preparation method of lotion | |
| CN103585417B (en) | Agentiafor treating idiopathic trigeminal neuralgia | |
| CN102698012A (en) | Externally applied traditional Chinese medicine for treating oral lichen planus | |
| CN113648352A (en) | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases | |
| CN103285044A (en) | High efficacy therapeutic agent for rhinitis and pharyngitis and making method | |
| CN108578595A (en) | A kind of pharmaceutical composition that treating chronic itch and its application | |
| CN101152201A (en) | Application of isoquercitrin in preparation of drugs for preventing and/or treating depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| DD01 | Delivery of document by public notice |
Addressee: Guo Zhibiao Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Guo Zhibiao Document name: Notification of Publication of the Application for Invention |
|
| DD01 | Delivery of document by public notice |
Addressee: Guo Zhibiao Document name: Notification of Patent Invention Entering into Substantive Examination Stage |
|
| DD01 | Delivery of document by public notice |
Addressee: Guo Zhibiao Document name: the First Notification of an Office Action |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Guo Zhibiao Document name: Notification of an Office Action |
|
| DD01 | Delivery of document by public notice | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150701 |